Anna C Sick1, Sarah Tschudin-Sutter2, Alison E Turnbull3, Scott J Weissman4, Pranita D Tamma5. 1. Department of Pediatrics, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania; 2. Department of Infectious Diseases and Hospital Epidemiology, University Hospital Basel, Basel, Switzerland; 3. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland; 4. Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington; and. 5. Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland ptamma1@jhmi.edu.
Abstract
BACKGROUND: Empirical combination antibiotic regimens consisting of a β-lactam and an aminoglycoside are frequently employed in the pediatric population. Data to demonstrate the comparative benefit of empirical β-lactam combination therapy relative to monotherapy for culture-proven Gram-negative bacteremia are lacking in the pediatric population. METHODS: We conducted a retrospective cohort study of children treated for Gram-negative bacteremia at The Johns Hopkins Hospital from 2004 through 2012. We compared the estimated odds of 10-day mortality and the relative duration of bacteremia for children receiving empirical combination therapy versus empirical monotherapy using 1:1 nearest-neighbor propensity-score matching without replacement, before performing regression analysis. RESULTS: We identified 226 matched pairs of patients well balanced on baseline covariates. Ten-day mortality was similar between the groups (odds ratio, 0.84; 95% confidence interval [CI], 0.28 to 1.71). Use of empirical combination therapy was not associated with a decrease in the duration of bacteremia (-0.51 days; 95% CI, -2.22 to 1.48 days). There was no survival benefit when evaluating 10-day mortality for the severely ill (pediatric risk of mortality III score ≥15) or profoundly neutropenic patients (absolute neutrophil count ≤100 cells/mL) receiving combination therapy. However, a survival benefit was observed when empirical combination therapy was prescribed for children growing multidrug-resistant Gram-negative organisms from the bloodstream (odds ratio, 0.70; 95% CI, 0.51 to 0.84). CONCLUSIONS: Although there appears to be no advantage to the routine addition of an aminoglycoside to a β-lactam as empirical therapy for children who have Gram-negative bacteremia, children who have risk factors for MDRGN organisms appear to benefit from this practice.
BACKGROUND: Empirical combination antibiotic regimens consisting of a β-lactam and an aminoglycoside are frequently employed in the pediatric population. Data to demonstrate the comparative benefit of empirical β-lactam combination therapy relative to monotherapy for culture-proven Gram-negative bacteremia are lacking in the pediatric population. METHODS: We conducted a retrospective cohort study of children treated for Gram-negative bacteremia at The Johns Hopkins Hospital from 2004 through 2012. We compared the estimated odds of 10-day mortality and the relative duration of bacteremia for children receiving empirical combination therapy versus empirical monotherapy using 1:1 nearest-neighbor propensity-score matching without replacement, before performing regression analysis. RESULTS: We identified 226 matched pairs of patients well balanced on baseline covariates. Ten-day mortality was similar between the groups (odds ratio, 0.84; 95% confidence interval [CI], 0.28 to 1.71). Use of empirical combination therapy was not associated with a decrease in the duration of bacteremia (-0.51 days; 95% CI, -2.22 to 1.48 days). There was no survival benefit when evaluating 10-day mortality for the severely ill (pediatric risk of mortality III score ≥15) or profoundly neutropenicpatients (absolute neutrophil count ≤100 cells/mL) receiving combination therapy. However, a survival benefit was observed when empirical combination therapy was prescribed for children growing multidrug-resistant Gram-negative organisms from the bloodstream (odds ratio, 0.70; 95% CI, 0.51 to 0.84). CONCLUSIONS: Although there appears to be no advantage to the routine addition of an aminoglycoside to a β-lactam as empirical therapy for children who have Gram-negative bacteremia, children who have risk factors for MDRGN organisms appear to benefit from this practice.
Authors: David X Li; Anna C Sick-Samuels; Nuntra Suwantarat; Rebecca G Same; Patricia J Simner; Pranita D Tamma Journal: Infect Control Hosp Epidemiol Date: 2017-12-05 Impact factor: 3.254
Authors: Anna C Sick-Samuels; Katherine E Goodman; Glenn Rapsinski; Elizabeth Colantouni; Aaron M Milstone; Andrew J Nowalk; Pranita D Tamma Journal: J Pediatric Infect Dis Soc Date: 2020-04-30 Impact factor: 3.164
Authors: Heidi Andersen; Natalia Connolly; Hansraj Bangar; Mary Staat; Joel Mortensen; Barbara Deburger; David B Haslam Journal: J Clin Microbiol Date: 2016-04-27 Impact factor: 5.948
Authors: Aline Fuchs; Julia Bielicki; Shrey Mathur; Mike Sharland; Johannes N Van Den Anker Journal: Paediatr Int Child Health Date: 2018-11 Impact factor: 1.990